<DOC>
	<DOCNO>NCT02305329</DOCNO>
	<brief_summary>Single-centre , open-label , randomize , two-sequence , two-way crossover study . The study consist two consecutive single-dose treatment period separate washout period 10 14 day .</brief_summary>
	<brief_title>Dosage Form Proportionality Opicapone To-Be-Marketed Formulation</brief_title>
	<detailed_description>Single-centre , open-label , randomize , two-sequence , two-way crossover study . The study consist two consecutive single-dose treatment period separate washout period 10 14 day . In Group 1 volunteer receive single oral dose 25 mg OPC . In Group 2 volunteer receive single oral dose 50 mg OPC</detailed_description>
	<mesh_term>Opicapone</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive ; Body mass index ( BMI ) 19 30 kg/m² ; Healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination , 12lead ECG ; Negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C vírus ( antiHCV ) antibody , antihuman immunodeficiency virus ( HIV ) 1/2 antibody screen ; Clinical laboratory test result clinically acceptable screen admission treatment period ; Negative screen alcohol drug abuse screen admission treatment period ; Nonsmokers exsmokers least 3 month ; Able willing give write informed consent ; If female : She childbearing potential reason surgery , childbearing potential , used effective nonhormonal method contraception ( intrauterine device intrauterine system ; condom occlusive cap [ diaphragm cervical vault cap ] spermicidal foam gel film cream suppository ; true abstinence ; vasectomize male partner , provide sole partner subject ) duration study ; negative serum pregnancy test screen negative urine pregnancy test Day 1 treatment period . A clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder ; A clinically relevant surgical history ; Any clinically relevant abnormality coagulation test ; Any clinically relevant abnormality liver function test . If subject borderline clinically relevant abnormality consider clinically significant , retest could do discussion sponsor 's medical monitor ; A history relevant atopy drug hypersensitivity ; A history alcoholism drug abuse ; Consume 14 unit alcohol week ; A significant infection know inflammatory process screen admission treatment period ; Acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period ; Used medicine within 2 week admission first period could affect subject 's safety study assessment investigator 's opinion ; Previously receive OPC . Previous use OPC document question subject ; Used investigational drug participate clinical trial within 90 day prior screen Participated 2 clinical trial within 12 month prior screen ; Donated receive blood blood product within 3 month prior screen ; Vegetarians , vegan medical dietary restriction ; Not able communicate reliably investigator ; Unlikely cooperate requirement study ; unwilling unable give write informed consent ; If female : pregnant breastfeeding ; positive serum pregnancy test ; childbearing potential use accept effective contraceptive method use oral contraceptive .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>